Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of genetic medicines, with a strong focus on rare neuromuscular diseases. The company’s primary expertise lies in ribonucleic acid (RNA)-targeted therapeutics, gene therapies, and other advanced genetic treatment modalities. Sarepta has developed and commercialized several approved therapies for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, addressing critical unmet needs for patients with progressive and life-limiting muscle disorders. Beyond Duchenne, its expansive pipeline encompasses treatments for limb-girdle muscular dystrophies and other neuromuscular as well as central nervous system disorders, with approximately 40 programs at various stages from discovery to clinical development. Sarepta Therapeutics plays a significant role in the biotechnology and pharmaceuticals sector, driving innovation in genetic medicine and affecting patient outcomes in rare disease communities worldwide.